Werewolf Therapeutics, Inc. (HOWL)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.06
- As of
Kresmion compiles this page from HOWL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Werewolf Therapeutics, Inc. (HOWL): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-21.
See the full HOWL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HOWL on one page. Preview it with sample data, then open it live with a free account.
Preview the HOWL dossierActive events for HOWL
- high13F: large reduction
CITADEL ADVISORS LLC cut 90% of HOWL (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 51% of HOWL (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 53% of HOWL (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 130.2%, EPS $0.08 vs $-0.2652 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 17.6% - EPS $-0.4 vs $-0.4855 estimate
FREE, NO ACCOUNT
Every event on HOWL, as it fires
You are seeing 5 of 7 events recorded on HOWL since 2026-06-10.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in HOWL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 95075A107 · 2026Q2 | $243K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 95075A107 · 2026Q2 | $22K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 95075A107 · 2026Q2 | $10K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, HOWL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HOWL against its peers
HOWL's return on equity of -245.2% ranks in the 24th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | HOWL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 806728 | n/a | 14 |
| Operating margin | n/a | -3536.5% | n/a | 12 |
| Net margin | n/a | -3449.0% | n/a | 12 |
| Return on equity | -245.2% | -109.5% | 24 | 18 |
Peers (24): RNTX, GANX, SGMOQ, LONA, ELTX, ELOX, CNTB, INKT, IMA, BMEA, BOLD, MREO, OSTX, HRTX, CRBU, XLO, ATNM, ALDX, GOSS, VRCA, HYPD, ATHE, KLRS, SER. Left out: APLM (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (HOWL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HOWL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HOWL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.